Status:
UNKNOWN
The Effect of Implant Coating (BoneMaster) on Migration and Clinical Outcome in Hip Arthroplasty With the Exceed Cup
Lead Sponsor:
University of Aarhus
Collaborating Sponsors:
Biomet Denmark Aps
Project coordinator Orthopaedic Centre, Aarhus
Conditions:
Osteoarthritis
Eligibility:
All Genders
55-75 years
Phase:
NA
Brief Summary
This study focuses on the effect of the hydroxyapatite coating with BoneMaster on the fixation of the hip prosthesis in primary hip alloplasty. A hemispheric joint cup of the type Exceed cup (Biomet) ...
Detailed Description
This study focuses on the effect of the hydroxyapatite coating with BoneMaster on the fixation of the hip prosthesis in primary hip alloplasty. A hemispheric joint cup of the type Exceed cup (Biomet) ...
Eligibility Criteria
Inclusion
- Symptomatic radiographic osteoarthritis
- Radiographically and clinically adequate bone quality with regard to a total hip prosthesis, including osteoporosis-Dexa-Scanning verification.
- Age 55 to 75 years
- Informed written consent
Exclusion
- Orthopaedic
- Other disease of affected hip than primary coxarthrosis at time of inclusion 1.1. Secondary osteoarthritis 1.1.1. sequelae after acetabular fracture 1.1.2. hip-near femoral fracture 1.1.3. calve perthe 1.1.4. dysplasia (severe) 1.1.5. other 1.2 Atraumatic caput necrosis
- Neuromuscular or vascular condition in one or the other lower extremity
- Immobilization postoperative for long periods, for instance because of other serious diseases, alloplasties of the other lower-extremity joint, etc (decided by investigator)
- Reoperation of affected hip because of 4.1 luxation (with closed or open reduction) 4.2 deep infection 4.3 fracture 4.4 aseptic loosening 4.5 other
- Body Mass Index (BMI) at time of inclusion 81-84 5.1 ≥ 35 kg/m2 (grade 2+3 85, Obese Class I 81) 5.2 \< 18,5 kg/m2 81-84
- Insufficient RSA marker spread or rigidity Operative
- Use of component other than Bimetric femoral stem (HA porous-coated without collar)
- Unsuitable bone quality for uncemented hip alloplasty, evaluated preoperatively
- Complications peroperatively on insertion of hip alloplasty that necessitate deviation for the described operative procedure (see section: "Operative procedure"), among others 9.1 per- and postoperative fracture 9.2 bone graft used peroperatively (treatment of bone defects, cysts, etc.) 9.3 screw fixation of the acetabulum 9.4 gluteal detachment or extensive femoral exposure 9.5 trochanter osteotomy 9.6 Under-reaming 1-2 mm (cup size is one mm larger than the reamer, i.e. reaming 51 mm, cup 52 mm) 9.7 Other Radiographic
- Cup placement 10.1 Cup inclination in AP (anteroposterior) plan \>56 degrees and \<35 degrees as evaluated on roentgenogram Medical
- Osteoporosis 11.1. previously diagnosed 11.2. project-related preoperative DEXA (dual energy x-ray absorptiometry ) scan Patients with osteoporosis on the scan (T-score \< -2.5) are excluded from the study with referral to medical osteoporosis treatment. Patients with osteopenia (T-score \< -1) are included in the project with referral to osteoporosis prophylactic treatment. Patients with osteopenia at project inclusion are DEXA re-scanned at the 2 year follow up.
- Arthritis 12.1. rheumatoid arthritis 12.2. psoriasis arthritis 12.3. other arthritides
- Metabolic bone disease 13.1. hyperparathyroidism 13.2. Paget bone disease 13.3. renal osteodystrophy 13.4. other
- Reduced kidney function thereby influencing bone metabolism
- Previous treatment of skeleton with radiation therapy
- Cancer Pharmaceuticals
- Pharmaceuticals that effect calcium-phosphorus metabolism and bone density 87-98, either through intermittent administration or as a constant dose 17.1. glucocorticoids (systemic) beyond short-term treatment (\<5 days) 17.2. immunosuppression/modulation (cyclosporine, methotrexate, etc.) Compliance related
- Absent patient compliance with treatment and follow-up investigations
- Abuse that the investigator feels would weaken compliance 19.1. alcohol abuse 19.2. medication abuse
- Psychological instability (including patient in treatment lithium/antidepressants/neuroleptics/ antipsychotic drugs) which the investigator feels would weaken compliance
Key Trial Info
Start Date :
January 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2024
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT02311179
Start Date
January 1 2013
End Date
August 1 2024
Last Update
November 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aarhus University Hospital
Aarhus, Denmark, 8000